



Dr. Stefanie Fischer

Oberärztin mbF

Medizinische Onkologie und Hämatologie · Dept. I

Kontakt

Dr. Stefanie Fischer
Switzerland

stefanie.fischer@kssg.ch

Homepage

www.kssg.ch/onkologie

Bereiche

Medizinische Onkologie und Hämatologie

Position

Oberärztin mbF

Forschungsgebiet

Urogenitale Tumoren
Klinische Forschung
Phase I Studien

Mitgliedschaften

ESMO, EAU, SGMO

Publikationen (29)

Su E, Christinat Y, McKee T, Azzarello-Burri S, Jochum W, Fischer S, Rothermundt C. BRCA2 germline mutation carrier with five malignancies: a case report. *Hered Cancer Clin Pract* 2024; 22:27.

Wosny M, Aeppli S, Fischer S, Peres T, Rothermundt C, Hastings J. Factors Guiding Clinical Decision-Making in Genitourinary Oncology. *Cancer Med* 2024; 13:e70304.

Fischer S, Gillessen S, Stalder O, Terbuch A, Cathomas R, Schmid F, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Alex Kluth L, Seifert B, Templeton A, Mingrone W, Ufe M, Fischer N, Beyer J, Woelky R, Omlin A, Vogl U, Hoppe K, Kamradt J, Rothschild S, Rothermundt C. First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). *Eur Urol Open Sci* 2024; 68:68-74.

Akhoundova D, Fischer S, Triscott J, Lehner M, Thienger P, Maletti S, Jacquet M, Lubis D, Bubendorf L, Jochum W, Rubin M. Rare histologic transformation of a CTNNB1 (β -catenin) mutated prostate cancer with aggressive clinical course. *Diagn Pathol* 2024; 19:83.

Mc Laughlin A, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio-Poretti M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, Stathis A, Halbherr S, Huisinga W, Jörgler M, Kloft C. Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. *Cancer Chemother Pharmacol* 2024; 94:349-360.

Peres T, Aeppli S, Fischer S, Gysel K, Rothermundt C. Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer. *J Cancer Res Clin Oncol* 2024; 150:84.

Boormans J, Sylvester R, Anson-Cartwright L, Glicksman R, Hamilton R, Hahn E, Daugaard G, Lauritsen J, Wagner T, Avuzzi B, Nicolai N, del Muro X, Aparicio J, Stalder O, Rothermundt C, Fischer S, Laguna M. Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office. *Eur Urol Oncol* 2023

Kelly W, Danila D, Lin C, Lee J, Matsubara N, Ward P, Armstrong A, Pook D, Kim M, Dorff T, Fischer S, Lin Y, Horvath L, Sumey C, Yang Z, Jurida G, Smith K, Connarn J, Penny H, Stieglmaier J, Appleman L. Xaluritamid, a STEAP1 \times CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. *Cancer Discov* 2023:OF1-OF14.

Templeton A, Omlin A, Berthold D, Beyer J, Burger I, Eberli D, Engeler D, Fankhauser C, Fischer S, Gillessen S, Nicolas G, Kroeze S, Lorch A, Müntener M, Papachristofilou A, Schäfer N, Seiler D, Stenner-Liewen F, Tsantoulis P, Vlajnic T, Zilli T, Zwahlen D, Cathomas R. Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer. *Swiss Med Wkly* 2023; 153:40108.

Silzle T, Kahlert C, Albrich W, Nigg S, Demmer-Steingruber R, Driessen C, Fischer S. Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study. *Swiss Med Wkly* 2023; 153:40090.

Patrikidou A, Cazzaniga W, Berney D, Boormans J, de Angst I, Di Nardo D, Fankhauser C, Fischer S, Gravina C, Gremmels H, Heidenreich A, Janisch F, Leão R, Nicolai N, Oing C, Oldenburg J, Shepherd R, Tandstad T, Nicol D. European Association of Urology Guidelines on Testicular Cancer: 2023 Update. *Eur Urol* 2023; 84:289-301.

Menges D, Piatti M, Omlin A, Cathomas R, Benamran D, Fischer S, Iselin C, Kueng M, Lorch A, Prause L, Rothermundt C, O'Meara Stern A, Zihler D, Lippuner M, Braun J, Cerny T, Puhan M. Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment. *Eur Urol Open Sci* 2023; 51:26-38.

Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Seifert B, Alex Kluth L, Ufe M, Mingrone W, Templeton A, Fischer N, Rothschild S, Woelky R, Gillessen S, Cathomas R. The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. *Eur Urol Open Sci* 2023; 50:57-60.

Neuenschwander A, Lonati C, Antonelli L, Papachristofilou A, Cathomas R, Rothermundt C, Templeton A, Gulamhusein A, Fischer S, Gillessen S, Hermanns T, Lorch A, Mattei A, Fankhauser C. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. *Eur Urol Focus* 2022

Fischer S, Götze T, Omlin A, Baird R, Dawson K, Zitt C, Arany Z, Tresch G, Fiedler U, Jeger S, Fung S, Legenne P, Leupin N, Schneeweiss A, Fremd C. A Case of Sustained Tumor Regression With MP0274, a Novel DARPIn Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab. *JCO Precis Oncol* 2022; 6:e2200006.

Aeppli S, Engeler D, Fischer S, Omlin A, Pratsinis M, Hermann C, Rothermundt C. Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018. *Swiss Med Wkly* 2022; 152:w30175.

Terbuch A, Posch F, Bauernhofer T, Jost P, Partl R, Stranzl-Lawatsch H, Baciarello G, Fizazi K, Giannatempo P, Verzoni E, Sweeney C, Ravi P, Tran B, Basso U, White J, Vincenzi B, Oing C, Cutuli H, Dieckmann K, Gamulin M, Chovanec M, Fankhauser C, Heidenreich A, Mohamad O, Thibault C, Fischer S, Gillessen S. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. *Int J Radiat Oncol Biol Phys* 2022; 113:825-832.

Seidel C, Hentrich M, Zschäbitz S, Paffenholz P, Heidenreich A, Nestler T, Tran B, Fischer S, Daugaard G, Ochsenreither S, Brito M, Zengerling F, Schwab C, Bokemeyer C, Oing C. Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). *World J Urol* 2022; 40:355-361.

Achard V, Putora P, Omlin A, Zilli T, Fischer S. Metastatic Prostate Cancer: Treatment Options. *Oncology* 2021; 100:48-59.

Beyer J, Stenner F, Spahn M, Seiler R, Rothermundt C, Roth B, Papachristofilou A, Omlin A, Lorch A, Honecker F, Hermanns T, Gross T, Gillessen S, Fischer S, Fankhauser C, Cathomas R, Bode P, Berthold D, Bühner E. Swiss germ-cell cancer consensus recommendations. *Swiss Med Wkly* 2021; 151

Fankhauser C, Tandstad T, Nicolai N, Nicol D, Leão R, Muilwijk T, Janisch F, Mayor de Castro J, Gremmels H, Fizazi K, Fischer S, Boormans J, Bokemeyer C, Algaba F, Albers P, Oldenburg J, Pilar Laguna M. Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. *Eur Urol* 2021; 80:4-6.

Baird R, Fischer S, Azaro A, Harstrick A, Stumpp M, Leupin N, Dawson K, Fiedler U, Zitt C, Rodón J, Harris A, Lord S, Middleton M, Linossi C, Omlin A. First-in-Human Phase I Study of MP0250, a First-in-Class DARPIn Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors. *J Clin Oncol* 2020; 39:145-154.

Fischer S, Clements S, McWilliam A, Green A, Descamps T, Oing C, Gillessen Sommer S. Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer. *Cancer Treat Res Commun* 2020; 25:100256.

Aeppli S, Sternberg C, Schmidinger M, Rini B, Porta C, Omlin A, Oldenburg J, McDermott D, Gruenwald V, Larkin J, Fischer S, Escudier B, Eisen T, Eboulet E, Rothermundt C. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. *ESMO Open* 2020; 5

Fischer S, Langberg C, Ståhl O, Fankhauser C, Hamid A, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen Sommer S, Wheeler M, Hentrich M, Heidenreich A, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Global Germ-Cell Cancer Group. Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. *J Clin Oncol* 2019;JCO1901876.

Fischer S, Ali O, Jochum W, Kluckert J, Flatz L, Siano M. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. *Oncol Res Treat* 2018; 41:391-394.

Fischer S, Cohn-Cedermark G, Ståhl O, Chau C, Arriola E, Marti K, Hutton P, Laguerre B, Maroto P, Beyer J, Dieckmann K, Lorch A, Tandstad T, Wheeler M, Porfiri E, Flechon A, Aparicio J, Klingbiel D, Skrbinc B, Basso U, Shamash J, Gillessen Sommer S. Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma. *J Clin Oncol* 2016; 35:194-200.

Fischer S, Gillessen Sommer S, Rothermundt C. Sequence of treatment in locally advanced and metastatic renal cell carcinoma. *Transl Androl Urol* 2015; 4:310-25.

Fischer S, Weber J, Senn-Schönenberger I, Cerny T, Hundsberger T. Neuroborreliosis Mimicking Leptomeningeal Carcinomatosis in a Patient With Breast Cancer: A Case Report. *J Investig Med High Impact Case Rep* 2014; 2:2324709614529417.

Projekte (14)

Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial.

Klinische Forschung - 31.10.2024 - 31.12.2028

Laufend

Eine doppelblinde, randomisierte Phase-III-Studie zur Bewertung der Wirksamkeit von ADT +/- Darolutamid bei Patienten mit neu metastasiertem Prostatakrebs mit gefährdeten funktionellen Fähigkeiten, die nicht für Docetaxel- oder einen anderen Androgenrezeptor gerichteten Wirkstoffe geeignet sind

Klinische Forschung - 18.10.2023 - 31.12.2028

Laufend

Dosiseskaltungs- und Erweiterungsstudie zur Sicherheit und Wirksamkeit von XL092 in Kombination mit immunonkologischen Wirkstoffen bei Patienten mit inoperablen fortgeschrittenen oder metastasierten soliden Tumoren

Klinische Forschung - 07.02.2023 - 31.12.2026

Laufend

Eine Phase-1-Studie mit AMG 509 bei Patienten mit metastasiertem kastrationsresistentem Prostatakrebs

Klinische Forschung - 30.11.2022 - 31.12.2026

Laufend

Covid 19 Impfantwort, Bedarf und Reaktion auf mögliche Booster- Impfung bei Patienten mit soliden Neoplasien

Klinische Forschung - 01.10.2021 - 28.02.2021

Automatisch geschlossen

SAKK 67/20 Open-label single-stage phase 1B study of the new micellar docetaxel compound Docecal in patients with advanced castration-resistant prostate cancer

Klinische Forschung - 28.05.2021 - 31.12.2024

Abgeschlossen

Response to COVID-19 vaccination and COVID-19 infections after vaccination in patients with haematological malignancies

Klinische Forschung - 01.05.2021 - 01.10.2022

Abgeschlossen

MK-7902-005 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

Klinische Forschung - 17.03.2021 - 07.05.2030

Laufend

EINE OFFENE, MULTIZENTRISCHE PHASE-II-STUDIE ZUR BEURTEILUNG DER SICHERHEIT UND WIRKSAMKEIT DER NEOADJUVANTEN UND ADJUVANTEN THERAPIE VON TIRAGOLUMAB PLUS ATEZOLOZUMAB MIT ODER OHNE PLATINBASIERTER CHEMOTHERAPIE BEI PATIENTEN MIT NICHT VORBEHANDELTEM LOKAL FORTGESCHRITTENEM OPERABLEM NICHT KLEINZELIGEM LUNGENKREBS IM STADIUM II, IIIA ODER EINER BESTIMMTEN FORM IM STADIUM IIIB

Klinische Forschung - 12.02.2021 - 24.07.2024

Abgebrochen

A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS

Klinische Forschung - 17.07.2020 - 17.07.2022

Automatisch geschlossen

SAKK 01/18 Reduced intensity radio-chemotherapy for satge IIA/B seminoma. A multicenter, open label phase II trial with 2 cohorts

Klinische Forschung - 24.07.2019 - 24.07.2030

Laufend

Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial

Klinische Forschung - 15.10.2015 - 31.12.2029

Laufend

An open-label, multicohort, phase II study of MPDL3280A in advanced solid tumors

Klinische Forschung - 08.07.2015 - 31.07.2019

Automatisch geschlossen

SAKK 96/12 - Verhinderung von symptomatischen Komplikationen am Skelett mit Denosumab verabreicht alle 4 Wochen gegenüber alle 12 Wochen

Klinische Forschung - 07.07.2014 - 31.12.2026

Laufend